Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129898 | 0.87 | CETP (0.43) | CETPL3MBTL1POLB | |
| SCHEMBL1587600 | 0.87 | CETP (0.49) | CETPL3MBTL1 | |
| SCHEMBL4496376 | 0.83 | CETP (0.46) | CETPKMT2AMEN1L3MBTL1 | |
| SCHEMBL13910237 | 0.82 | CETP (0.41) | CETPKMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1587680 | 0.82 | CETP (0.44) | CETPL3MBTL1 | |
| SCHEMBL131317 | 0.79 | CETP (0.40) | CETPKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL1587774 | 0.78 | CETP (0.57) | CETPLMNA | |
| SCHEMBL4493367 | 0.78 | CETP (0.43) | CETPKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1587797 | 0.78 | CETP (0.42) | CETPL3MBTL1 | |
| SCHEMBL1588631 | 0.77 | CETP (0.51) | CETPL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | CETP 1/4885KMT2A 544/4885MEN1 2509/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885KMT2A 544/4885MEN1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.